

## Surgery Network Travel Award – Kenneth Huang

1. Mirabal, JR, Taylor JA, Lerner SP. CIS of the Bladder: Significance and Implications for Therapy. *Bladder Cancer*. 2019;5(3):193-204.
2. LammDL, Blumenstein BA, CrissmanJD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol*. 2000;163(4):1124-1129.
3. Bhindi B, Kool R, Kulkarni GS, et al. Canadian Urological Association guideline on the management of non-muscle-invasive bladdercancer –Full-text. *Can UrolAssoc J* 2021;15(8):E424-57.
4. SwietekN, WaldertM, Rom M, et al. The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérininstillation therapy for nonmuscleinvasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature. *J Urol*.2012;188(3):748-753.

## Ovarian Cancer Prevention with Opportunistic Salpingectomy

1. Society, C.C. Cancer-specific stats. 2020; Available from: [https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2020-statistics/canadian-cancer-statistics/2020-resources/res-cancerstatistics-canadiancancerstatistics-2020\\_cancer-specific-stats.pdf?rev=a672053690e9493d921fe73453a749b4&hash=4F194657DA83EFC15ADB92A8E5ACBC5E](https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2020-statistics/canadian-cancer-statistics/2020-resources/res-cancerstatistics-canadiancancerstatistics-2020_cancer-specific-stats.pdf?rev=a672053690e9493d921fe73453a749b4&hash=4F194657DA83EFC15ADB92A8E5ACBC5E).
2. Powell, C.B., et al., Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. *Int J Gynecol Cancer*, 2011. 21(5): p. 846-51.
3. Tang, S., et al., Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. *Int J Gynecol Pathol*, 2012. 31(2): p. 103-10.
4. Hanley, G.E., et al., Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. *JAMA Netw Open*, 2022. 5(2): p. e2147343.
5. Hanley, G.E., et al., Opportunistic salpingectomy for ovarian cancer prevention. *Gynecol Oncol Res Pract*, 2015. 2: p. 5.

6. McAlpine, J.N., et al., Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. *Am J Obstet Gynecol*, 2014. 210(5): p. 471 e1-11.
7. Hanley, G.E., et al., The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. *Am J Obstet Gynecol*, 2017. 216(3): p. 270 e1-270 e9.
8. Hanley, G.E., et al., Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. *Am J Obstet Gynecol*, 2018. 219(2): p. 172 e1-172 e8.
9. Hanley, G.E., et al., Examining indicators of early menopause following opportunistic salpingectomy: A cohort study from British Columbia, Canada. *American Journal of Obstetrics & Gynecology*, 2020.
10. Hu, F.B., et al., Age at natural menopause and risk of cardiovascular disease. *Arch Intern Med*, 1999. 159(10): p. 1061-6.
11. Naumann, R.W., et al., The Impact of Opportunistic Salpingectomy on Ovarian Cancer Mortality and Healthcare Costs: A Call For Universal Insurance Coverage. *Am J Obstet Gynecol*, 2021.
12. American College of Obstetrics & Gynecology, Committee opinion no. 620: salpingectomy for ovarian cancer prevention. *Obstet Gynecol*, 2015. 125(1): p. 279-81.
13. Royal College of Obstetricians and Gynaecologists, The Distal Fallopian Tube as the Origin of Non-Uterin Pelvic High-Grade Serous Carcinomas. 2014: United Kingdom.
14. Society of Gynecologic Oncology, SGO Clinical Practice Statement: Salpingectomy for Ovarian Cancer. 2013.
15. The Society of Gynecologic Oncology of Canada, GOC Statement regarding salpingectomy and ovarian cancer prevention. 2011.
16. Tomasch, G., et al., Would women accept opportunistic (prophylactic) salpingectomy at the time of nongynecologic surgery to prevent development of ovarian cancer? *Surgery*, 2018. 164(5): p. 931-934.
17. Tomasch, G., et al., Prophylactic salpingectomy for prevention of ovarian cancer at the time of elective laparoscopic cholecystectomy. *Br J Surg*, 2020. 107(5): p. 519-524.

### Update on Merkel Cell Cancer

1. Gauci ML, Aristei C, Becker JC, et al. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. *Eur J Cancer*. 2022;171:203-231. doi:10.1016/j.ejca.2022.03.043
2. Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. *J Am Acad Dermatol*. 2018;78(3):457-463.e2. doi:10.1016/j.jaad.2017.10.028
3. Garbutcheon-Singh KB, Curchin DJ, McCormack CJ, Smith SD. Trends in the incidence of Merkel cell carcinoma in Victoria, Australia, between 1986 and 2016. *Australas J Dermatol*. 2020;61(1):e34-e38. doi:10.1111/ajd.13131

4. Harms KL, Healy MA, Nghiem P, et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. *Ann Surg Oncol*. 2016;23(11):3564-3571. doi:10.1245/s10434-016-5266-4
5. NCCN Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma. National Comprehensive Cancer Network. [https://www.nccn.org/professionals/physician\\_gls/pdf/mcc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf). Published March 24, 2022. Accessed September 20, 2022.
6. Singh N, Alexander NA, Lachance K, et al. Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. *J Am Acad Dermatol*. 2021;84(2):330-339. doi:10.1016/j.jaad.2020.07.065
7. Andruska N, Fischer-Valuck BW, Mahapatra L, et al. Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma. *JAMA Dermatol*. 2021;157(5):540-548. doi:10.1001/jamadermatol.2021.0247
8. Tarabadkar ES, Fu T, Lachance K, et al. Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm. *J Am Acad Dermatol*. 2021;84(2):340-347. doi:10.1016/j.jaad.2020.07.079
9. Jaouen F, Kervarrec T, Caille A, et al. Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: A retrospective study. *J Am Acad Dermatol*. 2021;84(4):921-929. doi:10.1016/j.jaad.2020.11.038
10. Nguyen AT, Luu M, Lu DJ, et al. Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. *J Am Acad Dermatol*. 2021;84(2):312-320. doi:10.1016/j.jaad.2019.12.072
11. D'Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. *J Immunother Cancer*. 2020;8(1):e000674. doi:10.1136/jitc-2020-000674
12. D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. *JAMA Oncol*. 2018;4(9):e180077. doi:10.1001/jamaoncol.2018.0077
13. Nghiem P, Bhatia S, Lipson EJ, et al. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. *J Clin Oncol*. 2019;37(9):693-702. doi:10.1200/JCO.18.01896
14. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. *N Engl J Med*. 2016;374(26):2542-2552. doi:10.1056/NEJMoa1603702